PDX Pharmaceuticals Inc.'s ARAC-02 has been selected to enter the Nanotechnology Characterization Laboratory (NCL)'s Assay Cascade Characterization Program.
Following a missed primary endpoint in its phase III study in treating anti-PD-1-refractory advanced melanoma, Idera Pharmaceuticals Inc. is considering stopping the registrational trial of its synthetic Toll-like receptor 9 (TLR9) agonist or pressing on toward the clinical trial’s second primary endpoint.
Checkmate Pharmaceuticals Inc., of Cambridge, Mass., completed an $85 million series C to continue developing CMP-001, a differentiated Toll-like receptor 9 (TLR9) agonist, for treating anti-PD-1-refractory melanoma and to study additional indications that include front-line melanoma and head and neck squamous cell carcinoma.